Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Mitochondrial approaches for neuroprotection.
A high-density screen for linkage in multiple sclerosis.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
Sanofi withdraws Campath in US and EU
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
European Congress of Immunology 2012
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
Biomarkers for Brain Disorders: Challenges and Opportunities
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Motor skill learning requires active central myelination.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.

Pages